Information  X 
Enter a valid email address

Xenova Group PLC (XEN)

  Print      Mail a friend

Tuesday 17 June, 2003

Xenova Group PLC

Research Update

Xenova Group PLC
17 June 2003

                              Xenova Group plc
           Results of second Phase IIa dose escalation study of TA-CD
                  vaccine for treatment of cocaine dependence

Slough, UK, 17 June, 2003 - Xenova Group plc (NASDAQ NM: XNVA; London Stock
Exchange: XEN) today reported the results of a second Phase IIa study for TA-CD,
its candidate therapeutic vaccine for the treatment of cocaine dependence.  The
results of this dose escalation trial, which was carried out by Professor Thomas
Kosten at Yale University, were announced at the 65th Annual Meeting of The
College on Problems of Drug Dependence at Bal Harbour, Florida 14-19th June.

TA-CD is being developed with the goal of assisting cocaine abusers in their
attempt to quit cocaine. This new trial, which is the second Phase II study to
be carried out on TA-CD, started in April 2002.  It involved the enrolment of 13
subjects, all of whom were cocaine abusers seeking help with their addiction at
the start of the trial.  Patients were treated with up to five injections of the
vaccine over a twelve week period using doses up to 360 (micro)g each. Of the
thirteen enrolled, twelve subjects completed the 12 month evaluation period to
assess safety, immune response and cocaine usage.

The results showed the vaccine to be safe and well tolerated with a dose-related
immune response.  Of those 16 patients in the two Phase IIa studies who used
cocaine at any time following vaccination, 14 reported a reduction of the usual
euphoric effect normally associated with cocaine use, providing further
anecdotal evidence of the vaccine's proposed mode of action.

'This trial is another important milestone for this programme and paves the way
for the start of forthcoming efficacy trials,' commented David Oxlade, Chief
Executive of Xenova.

This study is being funded, in part, by the US National Institute on Drug Abuse
(NIDA). NIDA has also supported earlier clinical work on TA-CD

                                   -- ends --

UK:                                               US:
Xenova Group plc                                  Trout Group/BMC Communications
Tel: +44 (0)1753 706600                           Tel: 001 212 477 9007
David A Oxlade, Chief Executive Officer           Press: Brad Miles (Ext 17) Daniel Budwick (Ext 14)
Daniel Abrams, Group Finance Director             Investors: Jonathan Fassberg (Ext 16) Lee Stern
Jon Davies, Corporate Communications              (Ext 22)

Financial Dynamics
Tel: +44 (0)207 831 3113
David Yates/Ben Atwell

Notes to Editors

About Xenova Group

Xenova Group plc's product pipeline focuses principally on the therapeutic areas
of cancer and immune system disorders.  Xenova has a broad pipeline of
programmes in clinical development.  The Group has a well-established track
record in the identification, development and partnering of innovative products
and technologies and has partnerships with significant pharmaceutical and
biopharmaceutical companies including Lilly, Pfizer, Celltech, Genentech, QLT
and Millennium Pharmaceuticals.

TA-CD is designed for use alongside a behavioural therapy program in patients
who are trying actively to overcome their cocaine addiction. TA-CD represents a
completely new approach to the treatment of cocaine addiction by way of immune
intervention.  The vaccine aims to build an antibody response against the drug
which will neutralize its effect on the brain.  The results of an earlier
four-dose Phase IIa dose escalation study were reported in July 2001. Patient
dosing for a Phase IIa cocaine administration trial commenced in April 2003.

Regular cocaine users number more than two million in the U.S. alone.  Of these,
approximately 900,000 seek treatment each year.  Most cocaine addicts are
treated by a specialist physician or psychiatrist in drug rehabilitation
centres. However, due to a high relapse rate reported with current treatment,
there is a clear need for an effective treatment to be used alongside a
behavioural therapy program, where currently nothing is available.

For further information about Xenova and its products please visit the Xenova
website at

For Xenova: Disclaimer to take advantage of the 'Safe Harbor' provisions of the
US Private Securities Litigation Reform Act of 1995. This press release contains
'forward-looking statements,' including statements about the discovery,
development and commercialization of products. Various risks may cause Xenova's
actual results to differ materially from those expressed or implied by the
forward looking statements, including: adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection for our
discoveries; commercial limitations imposed by patents owned or controlled by
third parties; our dependence upon strategic alliance partners to develop and
commercialize products and services; difficulties or delays in obtaining
regulatory approvals to market products and services resulting from our
development efforts; the requirement for substantial funding to conduct research
and development and to expand commercialization activities; and product
initiatives by competitors.  For a further list and description of the risks and
uncertainties we face, see the reports we have filed with the Securities and
Exchange Commission.  We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

                      This information is provided by RNS
            The company news service from the London Stock Exchange